VIR

Vir Biotechnology, Inc. (VIR) - Q1 2026 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended March 31, 2026. Vir Biotechnology is a clinical-stage biopharmaceutical company focused on infectious diseases (specifically chronic hepatitis delta) and oncology (dual-masked T-cell engagers). The company operates as a single reportable segment and continues to rely on external funding and collaborations to advance its pipeline.

Key Financial Metrics

Note: Total revenues for Q1 2026 were negative due to a reversal in license and collaboration revenue.

Material Changes vs. Prior Period

• Revenue Decline: Total revenues dropped from $3.0 million in Q1 2025 to a negative $29 thousand in Q1 2026. This was driven by a decrease in grant revenue (expiration of Gates Foundation agreements) and other revenue (reduced clinical supply sales to Brii Bio Parent), partially offset by a nominal improvement in license revenue.
• Operating Expenses: Total operating expenses decreased by $10.3 million to $132.3 million. R&D expenses declined primarily due to the absence of a $30.0 million one-time expense related to the Alnylam agreement amendment in Q1 2025 and R&D cost reimbursements from the Norgine collaboration. This was partially offset by higher contract manufacturing and clinical costs for the CHD and oncology programs.
• Capital Raise: In February 2026, the company completed a follow-on public offering, issuing approximately 20.3 million shares for net proceeds of $162.3 million. This significantly bolstered liquidity compared to the prior year.
• Investment Income: Interest income decreased to $7.2 million from $12.3 million due to lower interest rates and investment balances. The company also recognized an unrealized loss of $0.2 million on its equity investment in Brii Bio Parent, compared to a gain of $6.4 million in the prior year.

Guidance, Outlook, and Strategic Developments

• Liquidity: As of March 31, 2026, the company held $809.3 million in cash, cash equivalents, and investments. Management believes this is sufficient to fund operations for at least 12 months from the filing date.
• Major Collaboration (Subsequent Event): On April 15, 2026, Vir closed a global strategic collaboration with Astellas US LLC for VIR-5500 (a PSMA-targeted TCE for prostate cancer). The deal includes a $240 million upfront payment (expected within 30 days of closing) and a $75 million equity investment from Astellas. The company is eligible for up to $1.37 billion in future milestones.
• Clinical Pipeline:
  • CHD: The ECLIPSE registrational program is fully underway. Topline data for ECLIPSE 1 is expected in Q4 2026.
  • Oncology: Phase 1 studies for VIR-5500, VIR-5818 (HER2), and VIR-5525 (EGFR) are ongoing. Positive updated Phase 1 data for VIR-5500 was presented at ASCO 2026.
• Management Change: Mark Eisner, MD, Executive Vice President and Chief Medical Officer, announced his departure effective April 24, 2026. A search for a successor has been initiated.
• Risks: The company faces standard biotech risks including clinical trial failure, regulatory delays, and the need for additional capital. Specific risks include reliance on third-party CDMOs and the uncertainty of milestone payments under collaboration agreements.

Investor Verification Checklist

• Verify the timing and receipt of the $240 million upfront payment from the Astellas collaboration.
• Monitor the progress of the ECLIPSE 1 Phase 3 trial for the tobevibart/elebsiran combination, with data expected in late 2026.
• Assess the impact of the CMO departure on clinical development timelines and the recruitment of a new CMO.
• Review the burn rate relative to the $809 million cash position to confirm the 12-month runway projection.
• Track the status of the Norgine collaboration cost-sharing and reimbursement mechanisms for the CHD program.